Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Xiaobing Wang,Xin Wu,Binghe Tan,Liang Zhu,Yi Zhang,Li Lin,Yi Xiao,An Sun,Xinyi Wan,Shiyuan Liu,Yanfang Liu,Na Ta,Hang Zhang,Jialin Song,Ting Li,Ling Zhou,Jian Yin,Lingying Ye,Hongjuan Lu,Jinwei Hong,Hui Cheng,Ping Wang,Weiqing Li,Jianfeng Chen,Jin Zhang,Jing Luo,Miaozhen Huang,Lehang Guo,Xiaoming Pan,Yi Jin,Wenjing Ye,Lie Dai,Jian Zhu,Lingyun Sun,Biao Zheng,Dali Li,Yanran He,Mingyao Liu,Huaxiang Wu,Bing Du,Huji Xu
DOI: https://doi.org/10.1016/j.cell.2024.06.027
IF: 64.5
2024-07-09
Cell
Abstract:Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its application. Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejection and treated one patient with refractory immune-mediated necrotizing myopathy and two patients with diffuse cutaneous systemic sclerosis with these cells. This study was registered at ClinicalTrials.gov (NCT05859997). The infused cells persisted for over 3 months, achieving complete B cell depletion within 2 weeks of treatment. During the 6-month follow-up, we observed deep remission without cytokine release syndrome or other serious adverse events in all three patients, primarily shown by the significant improvement in the clinical response index scores for the two diseases, respectively, and supported by the observations of reversal of inflammation and fibrosis. Our results demonstrate the high safety and promising immune modulatory effect of the off-the-shelf CAR-T cells in treating severe refractory autoimmune diseases.